Drugs & Therapy Perspectives

, Volume 27, Issue 2, pp 5–8 | Cite as

Eltrombopag: a guide to its use in chronic immune (idiopathic) thrombocytopenic purpura

Drug and Profile Report


  1. 1.
    Rodeghiero F, Stasi R, Gernsheimer T, et al. Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group. Blood 2009 Mar 12; 113(11): 2386–93PubMedCrossRefGoogle Scholar
  2. 2.
    Stasi R, Evangelista ML, Amadori S. Novel thrombopoietic agents: a review of their use in idiopathic thrombocytopenic purpura. Drugs 2008; 68(7): 901–12PubMedCrossRefGoogle Scholar
  3. 3.
    Newland A. Thrombopoietin mimetic agents in the management of immune thrombocytopenic purpura. Semin Hematol 2007 Oct; 44(4 Suppl. 5): S35–45PubMedCrossRefGoogle Scholar
  4. 4.
    Revolade (eltrombopag film-coated tablets): summary of product information. London: European Medicines Agency, 2010Google Scholar
  5. 5.
    Promacta® (eltrombopag): US prescribing information. Research Triangle Park (NC): GlaxoSmithKline, 2009Google Scholar
  6. 6.
    Erickson-Miller CL, Delorme E, Tian SS, et al. Preclinical activity of eltrombopag (SB-497115), an oral, non-peptide thrombopoietin receptor agonist. Stem Cells 2009; 27: 424–30PubMedCrossRefGoogle Scholar
  7. 7.
    Bussel J, Provan D, Shamsi T, et al. Effect of eltrombopag on platelet counts and bleeding during treatment of chronic idiopathic thrombocytopenic purpura: a randomised, double-blind, placebo-controlled trial. Lancet 2009 Feb 21; 373(9664): 641–8PubMedCrossRefGoogle Scholar
  8. 8.
    Bussel J, Psaila B, Saleh M, et al. Efficacy and safety of repeated intermittent treatment with eltrombopag in patients with chronic idiopathic thrombocytopenic purpura [abstract no. 3431]. Blood 2008; 112(11): 1176Google Scholar
  9. 9.
    Cheng G, Saleh MN, Marcher C, et al. Eltrombopag for management of chronic immune thrombocytopenia (RAISE): a 6-month, randomised, phase 3 study. Lancet. Epub 2010 Aug 23Google Scholar
  10. 10.
    Saleh MN, Bussel JB, Cheng G, et al. Long-term treatment of chronic immune thrombocytopenic purpura with oral eltrombopag: results from the EXTEND study [abstract no. 682]. Blood 2009; 114(12): 1326Google Scholar
  11. 11.
    Bussel JB, Cheng G, Saleh MN, et al. Eltrombopag for the treatment of chronic idiopathic thrombocytopenic purpura. N Engl J Med 2007 Nov 29; 357(22): 2237–47PubMedCrossRefGoogle Scholar
  12. 12.
    Bussel JB, McHutchison J, Provan D, et al. Safety of eltrombopag, an oral non-peptide platelet growth factor, in the treatment of thrombocytopenia: results of four randomized, placebo-controlled studies [abstract no. 1299]. Blood 2007; 110(11): 391aGoogle Scholar
  13. 13.
    Garnock-Jones KP, Keam SJ. Eltrombopag. Drugs 2009; 69(5): 567–76PubMedCrossRefGoogle Scholar

Copyright information

© Adis Data Information BV 2011

Personalised recommendations